文献速递肝病

纤维化非酒精性脂肪性肝炎评分工具的建立与验证

Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-04-11

研究在意大利264例接受术中肝活检的重度肥胖者中建立并内部验证了纤维化非酒精性脂肪性肝炎(NASH)的无创评分FNI,该评分联合天冬氨酸氨基转移酶、高密度脂蛋白胆固醇和糖化血红蛋白。FNI在推导队列和3个欧洲外部验证队列中表现良好,推导队列AUROC为0.78,外部验证队列AUROC为0.80-0.95。

要点

  • FNI由天冬氨酸氨基转移酶、高密度脂蛋白胆固醇和糖化血红蛋白三项常规指标构成。
  • 推导队列排除切点0.10对应敏感度≥0.89、阴性预测值0.93;纳入切点0.33对应特异度≥0.90、阳性预测值0.57。
  • 外部验证队列中,排除切点敏感度0.87-1、阴性预测值0.99-1;纳入切点特异度0.73-0.94、阳性预测值0.12-0.49。

核心结论

  • FNI是一种准确、简单且可负担的无创评分,可用于在初级卫生保健中筛查糖代谢异常个体的纤维化NASH。

研究设计与样本

  • 推导队列纳入意大利罗马264例接受术中肝活检的重度肥胖个体。
  • 采用2000次自助抽样的逐步逻辑回归分析建立并内部验证最佳预测模型,以受试者工作特征曲线下面积(AUROC)评估性能。
  • 在3个独立欧洲高危NAFLD队列中进行外部验证:芬兰n=370、意大利n=947、英格兰n=5368。

主要发现

  • 最终预测模型命名为纤维化NASH指数(FNI),联合天冬氨酸氨基转移酶、高密度脂蛋白胆固醇和糖化血红蛋白。
  • FNI在推导队列和外部验证队列中对纤维化NASH的AUROC分别为0.78和0.80-0.95。
  • 推导队列中,排除切点0.10对应敏感度≥0.89、阴性预测值0.93;纳入切点0.33对应特异度≥0.90、阳性预测值0.57。
  • 外部验证队列中,排除切点敏感度0.87-1、阴性预测值0.99-1;纳入切点特异度0.73-0.94、阳性预测值0.12-0.49。

关键数值与推荐

  • 纤维化NASH定义为NASH、NAFLD活动度评分≥4且纤维化分期≥2。
  • 推导队列排除切点0.10对应敏感度≥0.89、阴性预测值0.93。
  • 推导队列纳入切点0.33对应特异度≥0.90、阳性预测值0.57。
  • 外部验证队列排除切点敏感度0.87-1、阴性预测值0.99-1。
  • 外部验证队列纳入切点特异度0.73-0.94、阳性预测值0.12-0.49。

临床怎么用

  • 原文结论认为FNI可用于在初级卫生保健中筛查糖代谢异常个体的纤维化NASH。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Noninvasive assessment of histological features of nonalcoholic fatty liver disease (NAFLD) has been an intensive research area over the last decade. Herein, we aimed to develop a simple noninvasive score using routine laboratory tests to identify, among individuals at high risk for NAFLD, those with fibrotic nonalcoholic steatohepatitis (NASH) defined as NASH, NAFLD activity score ≥4, and fibrosis stage ≥2. METHODS: The derivation cohort included 264 morbidly obese individuals undergoing intraoperative liver biopsy in Rome, Italy. The best predictive model was developed and internally validated using a bootstrapping stepwise logistic regression analysis (2000 bootstrap samples). Performance was estimated by the area under the receiver operating characteristic curve (AUROC). External validation was assessed in 3 independent European cohorts (Finland, n = 370; Italy, n = 947; England, n = 5368) of individuals at high risk for NAFLD. RESULTS: The final predictive model, designated as Fibrotic NASH Index (FNI), combined aspartate aminotransferase, high-density lipoprotein cholesterol, and hemoglobin A1c. The performance of FNI for fibrotic NASH was satisfactory in both derivation and external validation cohorts (AUROC = 0.78 and AUROC = 0.80-0.95, respectively). In the derivation cohort, rule-out and rule-in cutoffs were 0.10 for sensitivity ≥0.89 (negative predictive value, 0.93) and 0.33 for specificity ≥0.90 (positive predictive value, 0.57), respectively. In the external validation cohorts, sensitivity ranged from 0.87 to 1 (negative predictive value, 0.99-1) and specificity from 0.73 to 0.94 (positive predictive value, 0.12-0.49) for rule-out and rule-in cutoff, respectively. CONCLUSION: FNI is an accurate, simple, and affordable noninvasive score which can be used to screen for fibrotic NASH in individuals with dysmetabolism in primary health care.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Tavaglione F, Jamialahmadi O, De Vincentis A, et al. Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2022. PMID: 35421583. doi:10.1016/j.cgh.2022.03.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。